# A medicinal ledger of TB-500 effects, safety signals, and unknowns > TB-500 Effects: A Medicinal Research Safety Ledger — A medicinal research ledger separates reported TB-500 effects from cited safety signals, identity caveats, and the missing human evidence. **Rev3 / reader layer** Community reports are labeled as reports. Audited biological cautions are cited. The missing controlled blend or fragment data stays visible. ## The short version TB-500 is the short Ac-LKKTETQ fragment of thymosin beta-4. People discuss it mainly in connection with recovery, mobility, soreness, wound repair, and hair growth. The important divide is simple: those personal reports are not controlled human results. Most published repair evidence belongs to animals and often to the full-length parent protein rather than the TB-500 fragment. This page keeps the two columns separate. It lists the benefits and adverse effects described in research-use communities, then sets them beside the signed corpus's safety cautions. The central facts remain unchanged: the fragment has no completed controlled human trial, the long-term safety record is empty, and several concerns are theoretical because direct human studies do not exist. The [TB-500 research](/research) page holds the study detail; this page is the plain-language status view. ## What people report These are effects reported by research-use communities — **anecdotal, not clinical evidence**. Frequency labels describe how often a theme appeared in the corpus sources; they are not measured rates and do not prove that the peptide caused the experience. **Reported benefits** - **Faster recovery from tendon, ligament and muscle injuries — very commonly reported.** The dominant community theme is a faster return from soft-tissue injury, with wide variation and no controlled human confirmation. - **Less joint pain and stiffness, better range of motion — frequently reported.** People often pair less aching with easier movement; the reports do not establish cause. - **Improved overall flexibility and mobility — frequently reported.** Everyday movement and training can feel easier in some accounts, but the effect has not been measured under study conditions. - **Feeling of reduced inflammation or 'calmed down' soreness — occasionally reported.** Some accounts describe less swelling or post-exercise soreness; no human fragment trial confirms an anti-inflammatory effect. - **Better wound and skin healing — occasionally reported.** Cuts, surgical sites, and irritated skin appear in occasional stories, while the aligned wound literature is mainly animal work on the parent protein. - **Hair regrowth or thicker hair — rarely reported.** Hair change is a minor, inconsistent signal often mixed with other interventions. **Reported adverse effects** - **Injection-site redness, swelling or aching — very commonly reported.** Local soreness, redness, or swelling is the most repeated adverse report. - **Temporary tiredness or lethargy — frequently reported.** Short-lived tiredness is one of the more consistent whole-body complaints. - **Head rush, lightheadedness or headache — occasionally reported.** Brief lightheadedness and headache appear less often than fatigue or local reactions. - **Brief flu-like feeling — occasionally reported.** A small group describes a short run-down or feverish feeling early in use. - **Nausea — rarely reported.** Nausea is an uncommon and usually mild community report. - **Heightened awareness of an existing injury — rarely reported.** Some people say an old injury feels more noticeable; this is a sensation, not proof of repair activity. - **Temporary low mood or mood changes — rarely reported.** Short-lived mood changes appear rarely, with no clinical evidence linking them to TB-500. ## Safety and cautions **Human safety in people is essentially unstudied.** No completed controlled human trial has tested the TB-500 heptapeptide, so its safety profile in people remains unknown. [10] [6] **Theoretical cancer / tumor-growth concern.** The tumor concern is theoretical but biologically specific: full-length thymosin beta-4 has links to cell migration, angiogenesis, and tumor progression in laboratory research. [20] [21] **Banned in competitive sport (WADA-prohibited).** TB-500 is prohibited in tested sport, and analytical methods can detect the peptide and its breakdown products. [22] [10] **Reported benefits may overstate what the peptide actually does.** A long-term mouse study increased regenerating muscle fibers without improving strength, heart function, or fibrosis; a repair marker did not become a functional gain. [23] **TB-500 is a fragment, not the full thymosin beta-4 protein.** TB-500 is the Ac-LKKTETQ fragment, not full-length thymosin beta-4. Applying whole-protein findings to the fragment is an unconfirmed extrapolation. [22] [7] **Research-grade product quality is not guaranteed.** Unregulated research material can vary in identity, sequence, and purity, making both reactions and claimed results harder to interpret. [24] **Theoretical bleeding, surgery and clotting considerations.** **Theoretical caution.** Bleeding, surgery, and clotting concerns are theoretical. The corpus contains no direct human fragment study that measures those outcomes. **Theoretical caution in pregnancy, breastfeeding and the young.** **Theoretical caution.** Pregnancy, breastfeeding, and developmental cautions are also theoretical because cell movement and blood-vessel growth are basic developmental processes and no human safety data exist. --- The TB-500 record sorted onto one flat status board — each study dropped into its evidence row, the Ac-LKKTETQ fragment kept apart from its parent protein thymosin beta-4, and the empty human-trial row left in plain sight; no clinic stands behind the board and nothing here is dispensed or sold.